​

SpringWorks Therapeutics (SWTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SWTX Stock Forecast

SpringWorks Therapeutics (SWTX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $65.40, with a high of $78.00 and a low of $47.00. This represents a 39.18% increase from the last price of $46.99.

$30 $40 $50 $60 $70 $80 High: $78 Avg: $65.4 Low: $47 Last Closed Price: $46.99

SWTX Stock Rating

SpringWorks Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (63.64%), 4 Hold (36.36%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 4 7 Strong Sell Sell Hold Buy Strong Buy

SWTX Price Target Upside V Benchmarks

TypeNameUpside
StockSpringWorks Therapeutics39.18%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$62.50
Last Closing Price$46.99$46.99$46.99
Upside/Downside--33.01%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--6--6
May, 25--6--6
Apr, 2535---8
Mar, 2535---8
Feb, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 28, 2025Peter LawsonBarclays$47.00$46.181.78%0.02%
Jan 08, 2025Michael SchmidtGuggenheim$78.00$41.2089.32%65.99%
Aug 08, 2024Robert BurnsH.C. Wainwright$76.00$33.93123.99%61.74%
Aug 09, 2022H.C. Wainwright$94.00$39.66137.01%100.04%
May 27, 2022Wedbush$50.00$18.72167.09%6.41%
May 24, 2022Goldman Sachs$76.00$32.74132.13%61.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 29, 2025Cowen & Co.Holddowngrade
Apr 28, 2025GuggenheimBuyNeutraldowngrade
Jan 08, 2025GuggenheimBuyBuyhold
Aug 08, 2024H.C. WainwrightBuyBuyhold
Jun 18, 2022H.C. WainwrightBuyBuyhold
May 27, 2022WedbushOutperformOutperformhold
May 24, 2022Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.02$-3.57$-5.15$-3.48----
Avg Forecast$-1.37$-3.11$-4.92$-3.12$-2.12$-1.01$2.49$4.35
High Forecast$-1.07$-2.44$-4.77$-2.93$-0.66$0.24$3.75$5.51
Low Forecast$-1.61$-3.67$-5.34$-3.23$-3.36$-2.09$0.30$3.73
Surprise %-25.55%14.79%4.67%11.54%----

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$35.00M-$5.45M$191.59M----
Avg Forecast$21.00M$180.00$1.01M$186.88M$348.09M$588.47M$919.88M$1.16B
High Forecast$23.86M$216.00$1.84M$196.94M$418.56M$709.12M$1.11B$1.39B
Low Forecast$17.52M$144.00$583.21K$165.83M$309.17M$523.79M$818.78M$1.03B
Surprise %66.67%-441.11%2.52%----

Net Income Forecast

$-350M $-210M $-70M $70M $210M $350M Dec 20 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-44.24M$-173.21M$-325.10M$-258.13M----
Avg Forecast$907.63K$-128.42M$-325.10M$-194.19M$-147.81M$-44.49M$192.32M$274.59M
High Forecast$21.02M$-102.73M$-301.25M$-184.71M$-41.54M$14.91M$236.71M$347.78M
Low Forecast$-19.20M$-154.10M$-337.05M$-203.68M$-212.18M$-132.09M$18.94M$235.36M
Surprise %-4974.66%34.88%-32.92%----

SWTX Forecast FAQ

Is SpringWorks Therapeutics stock a buy?

SpringWorks Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that SpringWorks Therapeutics is a favorable investment for most analysts.

What is SpringWorks Therapeutics's price target?

SpringWorks Therapeutics's price target, set by 11 Wall Street analysts, averages $65.4 over the next 12 months. The price target range spans from $47 at the low end to $78 at the high end, suggesting a potential 39.18% change from the previous closing price of $46.99.

How does SpringWorks Therapeutics stock forecast compare to its benchmarks?

SpringWorks Therapeutics's stock forecast shows a 39.18% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for SpringWorks Therapeutics over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is SpringWorks Therapeutics’s EPS forecast?

SpringWorks Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.12, marking a -39.08% decrease from the reported $-3.48 in 2024. Estimates for the following years are $-1.01 in 2026, $2.49 in 2027, and $4.35 in 2028.

What is SpringWorks Therapeutics’s revenue forecast?

SpringWorks Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $348.09M, reflecting a 81.69% increase from the reported $191.59M in 2024. The forecast for 2026 is $588.47M, followed by $919.88M for 2027, and $1.16B for 2028.

What is SpringWorks Therapeutics’s net income forecast?

SpringWorks Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-148M, representing a -42.74% decrease from the reported $-258M in 2024. Projections indicate $-44.487M in 2026, $192.32M in 2027, and $274.59M in 2028.